Objectives: To assess the prevalence, levels of antimicrobial susceptibility and resistance mechanisms of Pseudomonas.
Introduction
The Gram-negative bacterium Pseudomonas aeruginosa is a ubiquitous aerobe that is present in water, in soil and on plants. Moreover, P. aeruginosa can be frequently isolated from tap water in patient rooms. 1 However, clinical isolates of P. aeruginosa appear to be more resistant to amoebal ingestion than environmental isolates. 2 P. aeruginosa accounts for a significant proportion of nosocomial infections. 3 A general problem with nosocomial infections is the tendency of nosocomial pathogens to acquire new antibiotic resistance. 4 Multidrug-resistant (MDR) strains of P. aeruginosa are often isolated among patients suffering from nosocomial infections, particularly those in the intensive care unit (ICU). 5 Thus, infections caused by P. aeruginosa are particularly problematic because the organism is inherently resistant to many drug classes and is able to acquire resistance to all effective antimicrobial drugs. 6 As an opportunistic infectious pathogen, P. aeruginosa can often lead to life-threatening diseases. For example, P. aeruginosa is the main cause of mortality in cases of polymicrobial bacteraemia, 7 and the second most common bacterium causing sepsis in the ICU. 8 In addition, P. aeruginosa has been implicated in urinary tract infections, burn wounds, ventilatorassociated pneumonia and multi-organ system failure. 9 -12 Therefore, it was important to study the susceptibility patterns of P. aeruginosa isolates to some commonly used antibiotics in Egypt. Use of the antibiogram as an epidemiological indicator for our isolates can help us make the best use of these antimicrobial agents in the management of P. aeruginosa infections. We also studied the prevalence of Pseudomonas species infections, especially P. aeruginosa, in hospitalized patients and in the hospital environment in Egypt. The high intrinsic antibiotic resistance of this organism is attributed to factors such as active drug efflux and b-lactamase production. 13 Thus, we concluded the study by testing these two possible mechanisms of resistance of the isolated P. aeruginosa to different antibiotics.
Materials and methods

Study design
A total of 445 clinical specimens were examined; 100 urine specimens (from patients with urinary tract infection), 45 stool specimens (from patients with gastrointestinal track infections), 50 sputum specimens (from patients with respiratory tract infections), 8 ear swab specimens (from patients with ear infections), 100 wound swab specimens, 45 abscess swab specimens and 25 burn swab specimens (from patients with wounds, abscesses, or burns). All specimens were collected from El-Minia University Hospital, El-Minia General Hospital and El-Minia Chest Hospital in Egypt. In addition, 200 environmental specimens were randomly collected from furniture, medical appliances and the surroundings of the same hospitals such as patients' beds, tables, ward sinks and surgical equipment. All specimens were examined for the existence of Pseudomonas species, and P. aeruginosa by standard procedures. 14, 15 Ethical approval to perform the study was obtained from the management boards of these hospitals and the Egyptian Ministry of Health and Population.
PCR detection of P. aeruginosa
This method was used before by Abd-El-Haleem et al. 16 for the detection of P. aeruginosa. Total bacterial DNA was prepared using the boiling approach. Bacterial cells were pelleted by centrifugation, resuspended in 50 mL of TE buffer and then lysed by boiling for 10 min. The lysate was centrifuged and the supernatant was transferred to a new tube. The crude cell lysate was used directly for PCR.
The primer pair PaLif (5 0 -ATGGAAATGCTGAAATTCGGC-3 0 ) and PaLir (5 0 -CTTCTTCAGCTCGACGCGACG-3 0 ) was selected in order to amplify conserved regions of a target gene in P. aeruginosa and thus generate a PCR amplicon with a certain molecular weight (504 bp) that can be identified by gel electrophoresis.
PCR assays were performed in a 50 mL volume with 2 U of DNA Taq polymerase (GIBCO PRL) in a thermal cycler (PTC-100 MJ Research, Watertown MA, USA). After initial denaturation for 2 min at 948C, 30 cycles were performed (the conditions for each cycle were: 30 s at 948C, 30 s at 518C and 1 min at 728C). The final cycle was followed by 728C incubation for 7 min. A reaction mixture containing sterile water was included as a negative control and a purified DNA mixture of the targeted bacteria was included as a positive control. The amplified PCR products were analysed by gel electrophoresis in 2% agarose gels stained with ethidium bromide, and then visualized and photographed in a Multi-Image light cabinet (Alpha Innotech Corporation, USA).
Antibiotics
The following antibiotics were obtained from the Egyptian market: ampicillin (Nile Pharmaceutical Company, Cairo, Egypt), ampicillin/sulbactam (Medical Union Pharmaceutical Company, Cairo, Egypt), amoxicillin (Egyptian International Pharmaceutical Industries Company; EIPICO, Cairo, Egypt), amoxicillin/clavulanate (Medical Union Pharmaceutical Company), cefalexin (Glaxo Wellcome, Cairo, Egypt), cefuroxime (Glaxo Wellcome), cefotaxime (Aventis Pharma, Cairo, Egypt), cefoperazone (Pharco Pharmaceuticals, Cairo, Egypt), ceftriaxone (EIPICO), cefepime (Bristol Myers Squibb; BMS, Cairo, Egypt), meropenem (Astra-Zeneca, Cairo, Egypt), gentamicin (Memphis for Pharmaceutical Chemical Industries Co., Cairo, Egypt), amikacin (Bristol Myers Squibb) and chloramphenicol (Chemical Industries Development; CID, Cairo, Egypt). Tetracycline, ciprofloxacin, levofloxacin, ofloxacin, norfloxacin and azithromycin were obtained from Sigma-Aldrich (St Louis, MO, USA).
Determination of MICs
The MICs of different antibiotics were determined by the agar dilution method, according to the CLSI (formerly known as the NCCLS) (1997), on Mueller -Hinton agar (MHA). Overnight cultures of tested organisms on Mueller -Hinton broth (MHB) were diluted to the initial cell density of $10 7 cfu/mL with fresh MHB. Inocula of $10 5 cfu per spot were applied to the surface of dry MHA plates containing graded concentrations (from 1-1024 mg/L) of the respective antibiotics. Plates were incubated at 378C for 18 -24 h and MICs were calculated. Spots with the lowest concentrations of antibiotic showing no growth were defined as the MIC.
b-Lactamase detection
The tested isolates were tooth-picked onto the surface of nutrient agar plates. After overnight incubation at 378C, the plates were overlaid with 1% molten agarose containing 0.2% soluble starch and 1% penicillin. The plates were incubated for 15 min at room temperature to solidify, and iodine solution was poured onto the agar plates. After 10 s, the residual iodine solution was damped out and the plates were incubated at room temperature until a discolouration zone appeared around b-lactamase-producing colonies. 17 Thus, the presence of a clear zone around bacterial growth is indicative of b-lactamase production.
Study of efflux system
We employed the method of Lomovskaya et al.
18 to study the efflux system of P. aeruginosa isolates. The MICs of four antibiotics of different groups (ciprofloxacin, meropenem, cefotaxime and gentamicin) for 25 MDR P. aeruginosa isolates were examined in the presence and absence of 10 mM of the efflux inhibitor carbonyl cyanide m-chlorophenylhydrazone (CCCP) (Sigma). The reduction in MIC of a certain antibiotic with CCCP is an indication of resistance to this antibiotic mediated by an efflux system.
Results
Prevalence of Pseudomonas species in clinical and environmental specimens
Out of the 445 clinical specimens, 107 Pseudomonas strains (24%) and 81 P. aeruginosa strains were isolated (18.2%). Out of the 200 environmental specimens, 57 Pseudomonas strains (28.5%) and 39 P. aeruginosa strains were isolated (19.5%), as shown in Tables 1 and 2 . From Table 1 , the percentage of P. aeruginosa isolates with respect to the total number of clinical Pseudomonas isolates can be calculated as 81/107 Â 100 ¼ 75.7%. From Table 2 , the percentage of P. aeruginosa isolates with respect to the total number of environmental Pseudomonas isolates can be calculated as 39/57 Â 100 ¼ 68.4%.
To further examine the percentage of P. aeruginosa isolates with respect to the total number of Pseudomonas isolates, 40 random Pseudomonas strains (20 clinical and 20 environmental) were examined biochemically and by PCR followed by gel electrophoresis and results were comparable (Figure 1 ). The average percentage of P. aeruginosa isolates with respect to the total number of clinical Pseudomonas isolates was 80%, whereas the average percentage of P. aeruginosa isolates with respect to the total number of environmental Pseudomonas isolates was 57.5%. Thus, the biochemical and molecular methods for identification of P. aeruginosa did not show a significant difference from our standard procedures for detecting the bacterium.
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MIC 90 s (MIC required to inhibit the growth of 90% of organisms) of each antibiotic, and whether the bacteria were susceptible, intermediately susceptible or resistant to each antibiotic. The breakpoint MIC of a drug is the highest concentration that can be safely attained in blood using the recommended dosing regimen. Organisms are considered susceptible to a drug if the MIC is below the breakpoint MIC. Organisms characterized by intermediate susceptibility are inhibited at concentrations that approach breakpoint. The MIC for a resistant organism surpasses the breakpoint MIC of the drug, and for that drug the risk of toxicity outweighs the potential benefits of therapy.
Among the antibiotics tested, amikacin was the most active drug against P. aeruginosa followed by meropenem, cefepime and fluoroquinolones. P. aeruginosa was highly resistant to all other antibiotics tested. In addition, the environmental isolates of P. aeruginosa exhibited higher antibiotic resistance than clinical isolates.
Resistance through b-lactamase production All P. aeruginosa isolates were subjected to b-lactamase detection. The presence of a clear zone around bacterial growth was indicative of b-lactamase production as described in the Materials and methods section. Our results showed that 29 (36%) of the clinical P. aeruginosa isolates and 37 (95%) of the environmental P. aeruginosa isolates were b-lactamase producers.
Resistance through the efflux system MDR nosocomial infections by P. aeruginosa are increasing worldwide. 19 The evolution of MDR bacteria can be attributed to the uncontrolled extensive use of antibiotics in hospitals and the community. 20 The evolution of MDR strains can be caused by an active efflux system that expels antibiotics from the cell. Table 7 shows the MICs of four antibiotics (ciprofloxacin, gentamicin, cefotaxime and meropenem) for 25 different MDR P. aeruginosa isolates in the presence and absence of the efflux inhibitor (CCCP). As can be seen from the table, the addition of CCCP enhanced the activities of ciprofloxacin and meropenem, but not gentamicin or cefotaxime. These results emphasized the presence of an efflux-mediated resistance in the tested strains to ciprofloxacin and meropenem, but not to gentamicin or cefotaxime.
Discussion
In this study, P. aeruginosa was the most prevalent species in the isolated strains. P. aeruginosa represented 75.7% of clinical The effectiveness of amikacin against P. aeruginosa is corroborated by data from other groups. 22, 23 One earlier study reported that meropenem was the most effective antibiotic against P. aeruginosa. 24 However, more recent studies demonstrated the evolution of meropenem-resistant strains of P. aeruginosa.
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Our study revealed moderate activity of quinolones towards P. aeruginosa. Whereas others reported similar rates of resistance to quinolones, 22, 27 Corona-Nakamura et al. 28 showed that P. aeruginosa was absolutely susceptible to ciprofloxacin. This discrepancy can be attributed to the continuous development of MDR strains of P. aeruginosa in different parts of the world.
The resistance pattern of P. aeruginosa to cephalosporins was consistent with the one reported by Yetkin et al. 23 who showed that the percentage of resistance to cephalosporins was in the range of 27% to 88%. Results in Tables 5 and 6 demonstrated that cefepime was the most active cephalosporin against P. aeruginosa. This is consistent with reports from several groups. 24, 28, 29 Additionally, the P. aeruginosa resistance pattern to gentamicin was close to the one reported by Muller-Premru and Gubina. 30 In order to define the main mechanisms used by P. aeruginosa to resist antibiotics, we tested for b-lactamase production and for the possess of efflux-mediated resistance. P. aeruginosa were previously shown to use b-lactamase-mediated resistance to antibiotics. 31 -33 We observed high levels of b-lactamase production in P. aeruginosa isolates (36% in clinical isolates and 95% in environmental isolates) in Minia similar to what has been reported elsewhere. 29 P. aeruginosa isolates in Minia also used efflux-mediated resistance to ciprofloxacin and meropenem, but not gentamicin or cefotaxime. Efflux-mediated fluoroquinolone resistance of P. aeruginosa was reported in several studies. 34 -36 Moreover, Pai et al. 37 reported that overproduction of the MexAB-OprM efflux system was associated with clinical episodes of carbapenem resistance in P. aeruginosa. Therefore, mechanisms of resistance used by P. aeruginosa isolates from Minia included b-lactamase production and the use of multiple drug resistance efflux pumps.
